Stock fact sheet · data as of
Translational Development Acquisition Corp. (TDAC): fair value, margin of safety and Wheel Score
Financial Services · Shell Companies · United States · Speculative / Distressed
Is TDAC undervalued?
TDAC closed at 10.81 on 16 Oct 2026 against a GLS average fair value of 11.77 - 8.2% below fair value, which our screens read as "fairly priced". 2 of 5 models are above the current price. There is no discount to lean on here, so the margin of safety is not the reason to look at the stock.
The 5 models disagree widely: EPV gives 3.65 while GLS Growth gives 20.11. A spread that wide means the average is sensitive to which methods you trust; the model table below shows where each one lands, and the Quote page lets you switch any of them off.
The nightly engine files TDAC under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for TDAC
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 8.10 | -25% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 18.79 | +74% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 8.21 | -24% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 20.11 | +86% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 3.65 | -66% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -0.2656 | -102% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: TDAC passes 3 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 2.3 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC 3.6%, ROE 3.6%, ROA 3.5% - with debt at 0.00 times equity and negative free cash flow.
Translational Development Acquisition Corp. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 10/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | 3.6% |
|---|---|---|---|
| GLS Moat | 2.3 / 10 | ROE | 3.6% |
| Debt / equity | 0.00 | ROA | 3.5% |
| Free-cash-flow yield | -0.3% | Payout ratio | 58% |
| Institutions | 10 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 32: No options
TDAC has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (32 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 10k shares a day on a market cap of $266M, with a beta of 0.01 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 16 / 25 | 8% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 3 / 15 | moat 2.3/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 6 / 20 | 10k shares/day, $266M cap, beta 0.01 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for TDAC in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Shell Companies
The 12 companies below are the closest to Translational Development Acquisition Corp. by market cap within the Shell Companies industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| PCAP ProCap Acquisition Corp | 10.40 | 4.16 | -150% | 13No options | $264M |
| DMAA Drugs Made In America Acquisition Corp. Ordinary Shares | 10.87 | 10.74 | -1% | 31No options | $264M |
| SOUL Soulpower Acquisition Corp. | 10.49 | 10.66 | +2% | 38No options | $269M |
| SORN Soren Acquisition Corp. | 10.02 | 0.9169 | -993% | 6No options | $264M |
| OBA Oxley Bridge Acquisition Limited | 10.40 | 12.56 | +17% | 36No options | $263M |
| ATII Archimedes Tech SPAC Partners II Co. Ordinary Shares | 8.86 | 0.0672 | -13092% | 16No options | $262M |
| OACC Oaktree Acquisition Corp. II | 10.65 | 12.68 | +16% | 39No options | $262M |
| GIW GigCapital8 Corp. | 10.20 | 1.77 | -476% | 6No options | $262M |
| FACT FACT II Acquisition Corp | 10.74 | 4.17 | -158% | 21No options | $261M |
| CEPV Cantor Equity Partners V, Inc. Class A Ordinary Shares | 10.20 | 5.46 | -87% | 7No options | $261M |
| PMTR Perimeter Acquisition Corp. I Class A Ordinary Shares | 10.44 | 3.86 | -171% | 13No options | $259M |
| PLMK Plum Acquisition Corp. IV | 10.63 | 9,909.56 | +100% | 39No options | $258M |
⚖ Compare TDAC with 7 of them All Financial Services stocks →
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about TDAC
Is TDAC undervalued right now?
Not meaningfully: at 10.81 the stock trades within a few percent of the GLS average fair value of 11.77 (8.2% below fair value, data as of 16 Oct 2026).
What is the Wheel Score of TDAC and what does it mean?
TDAC has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for TDAC?
11.77 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Translational Development Acquisition Corp. report earnings next?
No upcoming earnings date is recorded for TDAC in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does TDAC have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on TDAC, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.